2012-10-10 09:13:49 - New Pharmaceuticals market report from Global Markets Direct: "Moderate Psoriasis - Pipeline Review, H2 2012"

Global Markets Direct's, 'Moderate Psoriasis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Psoriasis. Moderate Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468462_moderate_psoriasis_pipeline_review_h2 ..


Note*: Certain sections in the report may be removed or altered based on the availability

and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Moderate Psoriasis.
* A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Moderate Psoriasis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Moderate Psoriasis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Moderate Psoriasis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Moderate Psoriasis Overview
Therapeutics Development
An Overview of Pipeline Products for Moderate Psoriasis
Moderate Psoriasis Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Moderate Psoriasis Therapeutics - Products under Development by Companies
Companies Involved in Moderate Psoriasis Therapeutics Development
Johnson & Johnson
Amgen Inc.
Eli Lilly and Company
ApoPharma
Idera Pharmaceuticals, Inc.
Deltanoid Pharmaceuticals Inc.
Vascular Biogenics Ltd.
CalciMedica, Inc.
Advancell
Moderate Psoriasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
brodalumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-811 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-517 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixekizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixekizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMO-3100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VB-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNTO-1959 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
becocalcidiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clobetasol Propionate + Etanercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CM-2489 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HO/02/10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Apo-805-K1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclosporine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Moderate Psoriasis Therapeutics - Drug Profile Updates
Moderate Psoriasis Therapeutics - Discontinued Products
Moderate Psoriasis - Product Development Milestones
Featured News & Press Releases
Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Moderate Psoriasis, H2 2012
Products under Development for Moderate Psoriasis - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468462&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.